Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Otsuka/Lundbeck’s Rexulti Appears Effective For Alzheimer’s Dementia Agitation, US FDA Says
Apr 12 2023
•
By
Sue Sutter
Rexulti could become the first approved treatment for agitation associated with Alzheimer's dementia. • Source: Shutterstock
More from US FDA Performance Tracker
More from Regulatory Trackers